RxDoctor Payments Data

Donna Bethel, DO

Family Medicine · Wichita, KSNPI 1730139437

Payments from drug & device makers

$7,399in general payments, 2019–2025

Across 432 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$860
  • AbbVie$709
  • Amgen$611
  • AstraZeneca$506
  • Astellas Pharma US Inc$432
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$7,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,399 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$45,663
Medicare patients
112
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$66,250
OzempicSemaglutide21$27,758
RybelsusSemaglutide17$24,043
JanuviaSitagliptin Phosphate18$19,826
JardianceEmpagliflozin14$19,510
TrulicityDulaglutide15$14,443
FarxigaDapagliflozin Propanediol25$14,296
Breo ElliptaFluticasone/Vilanterol18$11,239
XareltoRivaroxaban12$10,185
Aimovig AutoinjectorErenumab-Aooe11$9,964
MyrbetriqMirabegron13$6,206
Insulin Lispro Kwikpen U-100Insulin Lispro16$5,179
Novolog FlexpenInsulin Aspart14$5,150
SymbicortBudesonide/Formoterol Fumarate11$2,512
Liothyronine Sodium65$1,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$860$80,69482 claims
Novo NordiskOzempic, Rybelsus$1,649$51,80138 claims
MerckJanuvia$97$19,82618 claims
Boehringer IngelheimJardiance$13$19,51014 claims
AstraZenecaFarxiga, Symbicort$506$16,80836 claims
GSKBreo Ellipta$66$11,23918 claims
Johnson & JohnsonXarelto$65$10,18512 claims
Astellas Pharma US IncMyrbetriq$432$6,20613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,163170 claims
AbbVieSynthroid$709$50712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →